Fundraising FoxBroadOak Capital Partners — Full Portfolio
12 tracked investments · listed companies and verified rows first
PAK BioSolutions builds automated systems and single-use flow kits for end-to-end continuous purification of biopharmaceuticals, running four continuous purification stages simultaneously for a stated 4X productivity gain over batch methods.
Advanced ManufacturingBiotechHardwareBurke, US
Pezzini Joanna(President)inKevin Hill-Byrne(Co-Founder & CTO)in
Co-investorsArboretum Ventures
Indee Labs develops Hydropore™, a non-viral microfluidic technology for delivering molecules, nucleic acids, proteins, and gene-editing complexes into immune cells for engineered cell therapy research and manufacturing.
BiotechDeep TechHealthtechMedical DevicesSan Francisco, US
Ryan Pawell(CEO)inAdrian Lievano(Bioengineer)Amy Twite,Eva Welles(HR Consultant)
Co-investorsJude GomilaPioneerY CombinatorFounders FundMain Sequence VenturesSOSV
Kromatid provides single-cell structural genomic analysis tools for cell and gene therapy companies, enabling assessment of genomic integrity and identification of complex structural rearrangements during therapy development.
AI & Machine LearningBiotechDeep TechMedical DevicesLongmont, US
Andrew Jost(Executive Officer)James Chomas(Executive Officer, Director)Christopher Tompkins(Executive Officer, Director)Susan Bailey(Executive Officer)Joel Bedford(Director)
BoardTerry Opgenorth(Director)
PBS Biotech develops Vertical-Wheel bioreactors and related accessories for scalable manufacturing of cell therapies, including allogeneic therapies derived from induced pluripotent stem cells, mesenchymal stem cells, and CAR-T or NK cells.
BiotechHardwareMedical DevicesCamarillo, US
Brian Lee(Executive Officer, Director)inMatt Croughan(Executive Officer)Nelson Bermudez(Executive Officer)inTerrell Mathews(Executive Officer)inBryan Poltilove(Director)Jung Lim(Director)
Co-investorsAvego BioScience Capital
Pluristyx develops induced pluripotent stem cell (iPSC) technologies, including non-modified and genetically engineered cell lines, proprietary gene edits, and reprogramming platforms, along with related services.
BiotechDeep TechMedical DevicesSeattle, US
Benjamin Fryer(Co-Founder and Chief Executive Officer)inJason Carstens(Executive Officer, Director)Trent Carrier(Director)
Quartzy provides a platform for lab management and research resource optimization, serving life scientists, lab managers, and academic institutions.
BiotechDeep TechE-commerceEnterprise SoftwareHealthtechSaaSSan Francisco, US
Jayant Kulkarni(CEO)inAdam Regelmann(CPO)inAjoy Sojan(CTO)sylvie.dao@quartzy.comTristan Pemble(Director of Engineering)Courtney Bogaard(Director of HR)
Co-investorsA.Capital VenturesBling CapitalLerer HippeauMultiplier CapitalSilicon BadiaTeamworthy Ventures+10 more
S2.dev builds infrastructure services and tools for developers.
Cloud ComputingData & InfrastructureDeveloper ToolsEnterprise SoftwareSan Francisco, US
Shikhar Bhushan(CEO)inStephen Balogh(CTO)inDwarak Govind Parthiban(Founder)inMehul ArorainCristian Caciucin
Co-investorsGrayscale VenturesMaterialized View CapitalOrange CollectivePioneerTranspose Platform ManagementUncorrelated Ventures+11 more
seqWell develops reagents and technologies for next-generation sequencing library preparation, serving academic and institutional research clients.
BiotechDeep TechBeverly, US
Thomas Grant(Executive Officer)inDaniel Calvo(Executive Officer, Director)JoeJackJoseph Mellor(Executive Officer, Director)Joseph Mellor, Ph.D.(Executive Officer, Director)
Co-investorsResearch Corporation Technologies
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.